In the States
Select a state to learn more
State Activity
5/14/15: The Senate approved the House’s request for a conference committee, and appointed members to the conference committee
4/21/15: Senate referred the version of the bill that has been passed by the House to the Committee on Health and Human Services.
3/24/15: Committee substitute considered in committee; reported favorably as substituted.
3/17/15: House scheduled for a public hearing (notice, minutes and witness list).
2/18/15: Senate referred to Health & Human Services.
-
Bill Information
Amends the existing generic drug substitution law at section 562 of the Occupations Code.
Defines an “interchangeable biological product” as a biological product determined to be interchangeable by FDA or a product that has been deemed therapeutically equivalent by FDA.
Permits the dispensing of an interchangeable biological product in place of a prescribed biologic, provided that:
—pharmacist retains record of the substitution;
—pharmacist notifies the prescriber of the biologic dispensed within a reasonable time, electronically if possible (and by other means if not), except when there is no FDA-approved interchangeable biosimilar or the prescription is a refill that is unchanged from the prior filling;
—pharmacist labels the dispensed biologic with the name of the biologic, instructions for use, and other details;
—pharmacist labels the container with the words “Substituted for brand prescribed”;
—the selected biologic costs less to patient; and
—pharmacist does not charge a higher dispensing fee.
Requires a pharmacist to inform a patient regarding the cheaper biologic and inquire whether the patient is interested in substituting the biologics; except if the prescriber notified the patient that a biosimilar is available and the patient chose the brand prescribed or a biosimilar.
Directs pharmacies to post a sign stating “Texas law requires a pharmacist to inform you if a less expensive generically equivalent drug or interchangeable biological product is available for certain brand name drugs or products and to ask you to choose between the generic or interchangeable biological product and the brand name drug or product. you have a right to accept or refuse the generically equivalent drug or interchangeable biological product.”
Requires mail pharmacies to include language on the order form informing the patient of the option to choose biosimilars.
Establishes that a pharmacist who substitutes a biosimilar is not subject to greater liability than would be incurred in filling the biologic prescription.
-
Archive
World Congress and Expo on Biowavers and Biosimilars
December 6, 2011
September 10-12, 2012 San Antonio, Texas Read More
World Congress and Expo on Biowavers and Biosimilars
December 6, 2011
September 10-12, 2012 San Antonio, Texas Read More
Annual Luncheon Celebrating Women in Science
July 14, 2011
September 20, 2011 Rice Hotel Houston, TX Read More
Annual Luncheon Celebrating Women in Science
July 14, 2011
September 20, 2011 Rice Hotel Houston, TX Read More
BioHouston Breakfast Forum
July 14, 2011
June 21, 2011 Trevisio Restaurant – 6550 Bertner Street Houston, TX Read More
BioHouston Breakfast Forum
July 14, 2011
June 21, 2011 Trevisio Restaurant – 6550 Bertner Street Houston, TX Read More
10th Annual Life Sciences Technology Venture Forum
July 14, 2011
June 16, 2011 Rice University, Jones Graduate School of Business Houston, TX Read More
July 14, 2011
BioDFW BioHouston BioMed – San Antonio Health Industry Council of North Texas Houston Technology Center San Antonio Life Sciences Association Texas A&M Health Science Center Texas Bioscience Institute Texas Department of State Health Services Texas Emerging Technology Fund Texas Healthcare & Bioscience Institute Texas House of Representatives Texas Life Science Center Texas Life Sciences Collaboration […]
